Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aminophylline + ammonium chloride + diphenhydramine
- Development stage
- Unknown
- Lead developer
- Obsons Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aphylin is a fixed-dose combination syrup developed by Obsons Pharmaceuticals for the symptomatic relief of productive coughs and respiratory congestion associated with asthma, bronchitis, and the common cold. It contains aminophylline, a bronchodilator that relaxes bronchial smooth muscle via phosphodiesterase inhibition and adenosine receptor antagonism; diphenhydramine, an antihistamine that blocks histamine H1 receptors and muscarinic receptors to reduce allergic symptoms and suppress cough; and ammonium chloride, an expectorant that irritates the gastric mucosa to reflexively increase respiratory tract secretions and thin mucus. Aphylin is approved and marketed in Pakistan.
- Brand names
- Aphylin
- Other names
- aminophylline + ammonium chloride + diphenhydramineaminophylline + ammonium chloride + diphenhydramine hydrochloride
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)ADORA3 (Adenosine A3 receptor)HRH1 (Histamine H1 Receptor)HDAC2 (Histone deacetylase 2)mAChR (Muscarinic acetylcholine receptors)PDE3A (Phosphodiesterase 3A)PDE4APDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)
Beyond the preview
Go deeper on aminophylline + ammonium chloride + diphenhydramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aminophylline + ammonium chloride + diphenhydramine.